BIOLQ SEC फाइलिंग - BIOLASE, Inc.- वार्षिक रिपोर्ट, प्रॉक्सी स्टेटमेंट, प्रॉस्पेक्टस

मूलभूत आँकड़े

LEI	549300XJRS7X5LH3QM40
CIK	811240

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to BIOLASE, Inc.

SEC Filings (Chronological Order)

यह पृष्ठ SEC फाइलिंग की एक पूरी, कालानुक्रमिक सूची प्रदान करता है, ओनरशिप फाइलिंग को छोड़कर, जो हम अन्यत्र प्रदान करते हैं।

November 14, 2024	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 exhibit99-1.htm JOINT FILING AGREEMENT BY AND AMONG THE REPORTING PERSONS Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Stock, par value $0.001 per share, of BIOLASE, INC. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule
November 14, 2024	SC 13G/A	BIOL / BIOLASE, Inc. / Anson Funds Management LP - SC 13G/A Passive Investment SC 13G/A 1 d734083dsc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) (Amendment No.1) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) BIOLASE, INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 090911702 (CUSIP Number)
November 14, 2024	SC 13G/A	BIOL / BIOLASE, Inc. / Lind Global Fund II LP Passive Investment SC 13G/A 1 sch13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* BIOLASE, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 090911702 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to
November 7, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36385 BIOLASE, INC.
October 8, 2024	8-K	Current Report ‌ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 2, 2024 BIOLASE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36385 87-0442441 (State or other jurisdiction of incorporation) (Commission File No
October 1, 2024	8-K	Bankruptcy or Receivership ‌ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 30, 2024 BIOLASE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36385 87-0442441 (State or other jurisdiction of incorporation) (Commission File
October 1, 2024	EX-99.1	BIOLASE Voluntarily Initiates Chapter 11 Proceedings Exhibit 99.1 BIOLASE Voluntarily Initiates Chapter 11 Proceedings LAKE FOREST, Calif., October 1, 2024 – BIOLASE, Inc. (NASDAQ: BIOL) (the “Company”), a global leader in dental lasers, today announced that the Company and its direct domestic subsidiaries have voluntarily initiated Chapter 11 proceedings (the “Bankruptcy Petitions”) in the United States Bankruptcy Court for the District of Delaware
October 1, 2024	EX-10.1	Asset Purchase Agreement dated as of September 30, 2024, by and among BIOLASE, Inc., its subsidiaries named therein, and Sonendo, Inc. Exhibit 10.1 EXECUTION VERSION CONFIDENTIAL ASSET PURCHASE AGREEMENT BY AND AMONG SONENDO, INC., as Purchaser BIOLASE, INC., as Biolase BL ACQUISITION CORP., BL ACQUISITION II, INC., AND MODEL DENTAL OFFICE, LLC, collectively, as the Sellers Dated as of September 30, 2024 TABLE OF CONTENTS Page Article I DEFINITIONS 1 1.1 Certain Definitions 2 1.2 Terms Defined Elsewhere in this Agreement 15 Artic
September 6, 2024	EX-10.1	Forbearance Agreement dated as of August 31, 2024, by and between BIOLASE, Inc. and SWK Funding LLC as agent and lender. Exhibit 10.1 Execution Version FORBEARANCE AGREEMENT This FORBEARANCE AGREEMENT (this “Agreement”), dated as of August 31, 2024 is entered into by (i) BIOLASE, INC., a Delaware corporation (“Borrower”), SWK FUNDING LLC, a Delaware limited liability company, as agent (in such capacity “Agent”) and a Lender. RECITALS (a) Borrower, Agent, and Lenders are parties to that certain Credit Agreement, date
September 6, 2024	8-K	Current Report ‌ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 31, 2024 BIOLASE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36385 87-0442441 (State or other jurisdiction of incorporation) (Commission File No
August 28, 2024	8-K	Current Report ‌ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 28, 2024 BIOLASE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36385 87-0442441 (State or other jurisdiction of incorporation) (Commission File No
August 8, 2024	EX-99.1	BIOLASE REPORTS 2024 SECOND QUARTER RESULTS; ACHIEVES 40% GROSS MARGIN AS GLOBAL CONSUMABLE SALES STRENGTHEN Exhibit 99.1 BIOLASE REPORTS 2024 SECOND QUARTER RESULTS; ACHIEVES 40% GROSS MARGIN AS GLOBAL CONSUMABLE SALES STRENGTHEN LAKE FOREST, Calif., August 8, 2024 – BIOLASE, Inc. (NASDAQ: BIOL), a leader in dental laser technology, today reported its financial results for the second quarter ended June 30, 2024. “We experienced another strong quarter in consumable revenue, recording our second-highest m
August 8, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 BIOLASE, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36385 87-0442441 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
August 8, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36385 BIOLASE, INC. (Exac
July 22, 2024	8-K	‌ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 16, 2024 BIOLASE, INC. (Ex ‌ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 16, 2024 BIOLASE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36385 87-0442441 (State or other jurisdiction of incorporation) (Commission File No.)
June 18, 2024	8-K	‌ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 17, 2024 BIOLASE, INC. (Ex ‌ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 17, 2024 BIOLASE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36385 87-0442441 (State or other jurisdiction of incorporation) (Commission File No.)
June 3, 2024	EX-23.1A	Consent of Independent Registered Public Accounting Firm, Macias Gini & O’Connell LLP Exhibit 23.1(a) Consent of Independent Registered Public Accounting Firm BIOLASE, Inc. Lake Forest, California We hereby consent to the incorporation by reference in the Prospectus constituting a part of this Registration Statement on Form S-1 of our report dated March 21, 2024, relating to the consolidated financial statements and schedule listed in the index appearing under Item 15(a)(2), which
June 3, 2024	S-1	As filed with the Securities and Exchange Commission on June 3, 2024 As filed with the Securities and Exchange Commission on June 3, 2024 Registration No.
June 3, 2024	EX-23.1B	Consent of Independent Registered Public Accounting Firm, BDO USA, P.C. Exhibit 23.1(b) Consent of Independent Registered Public Accounting Firm BIOLASE, Inc. Lake Forest, California We hereby consent to the incorporation by reference in the Prospectus constituting a part of this Registration Statement of our report dated March 28, 2023, relating to the consolidated financial statements and schedule of BIOLASE, Inc. (the Company) appearing in the Company’s Annual Repo
June 3, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107.1 Calculation of Filing Fee Tables FORM S-1 (Form Type) BIOLASE, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price(1)(2) Fee Rate Amount of Registration Fee(3) Carry Forward Form
May 17, 2024	8-K	‌ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 17, 2024 BIOLASE, INC. (Exa ‌ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 17, 2024 BIOLASE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36385 87-0442441 (State or other jurisdiction of incorporation) (Commission File No.)
May 13, 2024	EX-99.1	BIOLASE REPORTS 2024 FIRST QUARTER RESULTS; REITERATES FULL-YEAR 2024 GUIDANCE FOR REVENUE GROWTH AND PROFITABILITY Increased Adoption of Dental Lasers and Improved Cost Structure Position Company for Sustained Long Term Growth and Success Exhibit 99.1 BIOLASE REPORTS 2024 FIRST QUARTER RESULTS; REITERATES FULL-YEAR 2024 GUIDANCE FOR REVENUE GROWTH AND PROFITABILITY Increased Adoption of Dental Lasers and Improved Cost Structure Position Company for Sustained Long Term Growth and Success LAKE FOREST, Calif., May 13, 2024 – BIOLASE, Inc. (NASDAQ: BIOL), a leader in dental laser technology, today reported its financial results for the
May 13, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36385 BIOLASE, INC. (Exa
May 13, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2024 BIOLASE, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36385 87-0442441 (State or Other Jurisdiction of Incorporation) (Commission File Number)
May 6, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 2, 2024 BIOLASE, INC. (Exact UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 2, 2024 BIOLASE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36385 87-0442441 (State or other jurisdiction of incorporation) (Commission File No.) (IR
April 23, 2024	424B4	Up to 2,249,000 Shares of Common Stock Underlying the Class A Warrants Up to 16,000,000 Shares of Common Stock Underlying the Class B Warrants BIOLASE, Inc. Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-276596 PROSPECTUS Up to 2,249,000 Shares of Common Stock Underlying the Class A Warrants Up to 16,000,000 Shares of Common Stock Underlying the Class B Warrants BIOLASE, Inc. This prospectus relates to the issuance of up to an aggregate of 18,249,000 shares of Common Stock, par value $0.001 per share (the “Common Stock”), of B
April 19, 2024	POS AM	As filed with the Securities and Exchange Commission on April 19, 2024 Table of Contents As filed with the Securities and Exchange Commission on April 19, 2024 Registration No.
April 19, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 19, 2024 BIOLASE, INC. (Exa UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 19, 2024 BIOLASE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36385 87-0442441 (State or other jurisdiction of incorporation) (Commission File No.)
April 11, 2024	EX-23.1(B)	Consent of Independent Registered Public Accounting Firm, BDO USA, P.C. Exhibit 23.1(b) Consent of Independent Registered Public Accounting Firm BIOLASE, Inc. Lake Forest, California We hereby consent to the incorporation by reference in the Prospectus constituting a part of this Registration Statement on Form S-1 (File No. 333-276596) of our report dated March 28, 2023, relating to the consolidated financial statements and schedules of BIOLASE, Inc. (the “Company”) a
April 11, 2024	EX-23.1(A)	Consent of Independent Registered Public Accounting Firm, Macias Gini & O’Connell LLP Exhibit 23.1(a) Consent of Independent Registered Public Accounting Firm BIOLASE, Inc. Lake Forest, California We hereby consent to the incorporation by reference in the Prospectus constituting a part of this Registration Statement on Form S-1 (File No. 333-276596) of our report dated March 21, 2024, relating to the consolidated financial statements and schedule listed in the index appearing under
April 11, 2024	POS AM	As filed with the Securities and Exchange Commission on April 11, 2024 Table of Contents As filed with the Securities and Exchange Commission on April 11, 2024 Registration No.
April 4, 2024	424B3	4,443,760 Shares Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-276280 PROSPECTUS 4,443,760 Shares Common Stock This prospectus relates to the resale from time to time of up to 4,443,760 shares of common stock, par value $0.001 per share (the “Common Stock”), of BIOLASE, Inc. issuable upon exercise of outstanding warrants, of which (i) 2,221,880 warrants (the “December 2023 Warrants”) were
March 28, 2024	CORRESP	BIOLASE, Inc. 27042 Towne Centre Drive, Suite 270 Lake Forest, California 92610 (949) 361-1200 BIOLASE, Inc. 27042 Towne Centre Drive, Suite 270 Lake Forest, California 92610 (949) 361-1200 March 28, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: BIOLASE, Inc. Registration Statement on Form S-1, as amended File No: 333-276280 Request for Acceleration of Effectiveness Ladies and Gentlemen: BIOLASE,
March 27, 2024	S-1/A	As filed with the Securities and Exchange Commission on March 27, 2024 Table of Contents As filed with the Securities and Exchange Commission on March 27, 2024 Registration No.
March 27, 2024	EX-23.1(A)	Consent of Independent Registered Public Accounting Firm, Macias, Gini & O’Connell, LLP Exhibit 23.1(a) Consent of Independent Registered Public Accounting Firm BIOLASE, Inc. Lake Forest, California We hereby consent to the incorporation by reference in the Prospectus constituting a part of this Registration Statement on Form S-1 (File No. 333-276280) of our report dated March 21, 2024, relating to the consolidated financial statements and schedule listed in the index appearing under
March 27, 2024	EX-23.1(B)	Consent of Independent Registered Public Accounting Firm, BDO USA, P.C. Exhibit 23.1(b) Consent of Independent Registered Public Accounting Firm BIOLASE, Inc. Lake Forest, California We hereby consent to the incorporation by reference in the Prospectus constituting a part of this Registration Statement on Form S-1 (File No. 333-276280) of our report dated March 28, 2023, relating to the consolidated financial statements and schedules of BIOLASE, Inc. (the Company) app
March 27, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) BIOLASE, Inc. (Exact Name of Registrant as Specified in its Charter) Table1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1)(3) Proposed Maximum Offering Price per Unit(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Previously paid Equity Common stock
March 22, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION REQUIRED INPROXYSTATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule14a-101) INFORMATION REQUIRED INPROXYSTATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material under §240.
March 22, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION REQUIRED INPROXYSTATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule14a-101) INFORMATION REQUIRED INPROXYSTATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under §240.
March 21, 2024	EX-10.27	Eleventh Amendment to Credit Agreement, dated as of November 15, 2023, by and between the Registrant and SWK LLC Exhibit 10.27 ELEVENTH AMENDMENT TO CREDIT AGREEMENT THIS ELEVENTH AMENDMENT TO CREDIT AGREEMENT (this “Amendment”), dated as of November 15, 2023, is entered into by and among BIOLASE, INC., a Delaware corporation (“Borrower”), each of the undersigned financial institutions (individually each a “Lender” and collectively “Lenders”) and SWK FUNDING LLC, a Delaware limited liability company, in its
March 21, 2024	EX-97.1	Clawback Policy Exhibit 97.1 BIOLASE, INC. Executive Officer Clawback Policy Approved by the Board of Directors on November 8, 2023 (the “Adoption Date”) i. Purpose This Executive Officer Clawback Policy describes the circumstances under which Covered Persons of Biolase, Inc., a Delaware corporation and any of its direct or indirect subsidiaries (the “Company”) will be required to repay or return Erroneously-Awar
March 21, 2024	EX-10.20	Indemnification Agreement between the Registrant and Jennifer Bright Exhibit 10.20 INDEMNIFICATION AGREEMENT This Indemnification Agreement (this “Agreement”) is entered into as of March 21, 2024 (the “Effective Date”), by and between BIOLASE, INC., a Delaware corporation (the “Company”), and Jennfier Bright (“Indemnitee”). RECITALS A. Indemnitee is either a member of the board of directors of the Company (the “Board of Directors”) or an officer of the Company, or
March 21, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36385 BIOLASE, INC.
March 21, 2024	EX-21.1	Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries BL Acquisition II, Inc. (Delaware) BL Acquisition Corp. (Delaware) Model Dental Office, LLC (Delaware) Biolase Australia, Pty. Ltd. (AUSTRALIA) Biolase Europe, GmbH (GERMANY) Biolase Spain, S.L. (SPAIN) Biolase India Private Limited (INDIA)
March 21, 2024	EX-4.1	Description of Registrant's Securities Registered Pursuant to Section 12 of the Exchange Act Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 BIOLASE, Inc. (“BIOLASE,” “we,” “us” or “our”) have two classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended, namely our (i) common stock, par value $0.001 per share (the “Common Stock”), and (ii) Series I Preferred Stock, p
March 21, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2024 BIOLASE, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36385 87-0442441 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
March 21, 2024	EX-10.21	Indemnification Agreement between the Registrant and Steven Sandor Exhibit 10.21 INDEMNIFICATION AGREEMENT This Indemnification Agreement (this “Agreement”) is entered into as of March 21, 2024 (the “Effective Date”), by and between BIOLASE, INC., a Delaware corporation (the “Company”), and Steven Sandor (“Indemnitee”). RECITALS A. Indemnitee is either a member of the board of directors of the Company (the “Board of Directors”) or an officer of the Company, or bo
March 21, 2024	EX-99.1	BIOLASE REPORTS FULL-YEAR 2023 RESULTS; EXPECTS CONTINUED REVENUE GROWTH IN 2024 Exhibit 99.1 BIOLASE REPORTS FULL-YEAR 2023 RESULTS; EXPECTS CONTINUED REVENUE GROWTH IN 2024 LAKE FOREST, Calif., March 21, 2024 – BIOLASE, Inc. (NASDAQ: BIOL), the globally recognized leader in dental laser technology, who previously announced its preliminary financial results for the fourth quarter and full year ended December 31, 2023, today reported its financial results for the quarter and f
March 8, 2024	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION REQUIRED INPROXYSTATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule14a-101) INFORMATION REQUIRED INPROXYSTATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under §240.
March 5, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 4, 2024 BIOLASE, INC. (Exac UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 4, 2024 BIOLASE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36385 87-0442441 (State or other jurisdiction of incorporation) (Commission File No.) (
February 27, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 26, 2024 BIOLASE, INC. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 26, 2024 BIOLASE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36385 87-0442441 (State or other jurisdiction of incorporation) (Commission File No
February 23, 2024	SC 13G	BIOL / BIOLASE, Inc. / S.H.N. Financial Investments Ltd. - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 BIOLASE, Inc. (Name of Issuer) Common stock, par value $0.001 (Title of Class of Securities) 090911702 (CUSIP Number) February 13, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐ Rul
February 21, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 20, 2024 BIOLASE, INC. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 20, 2024 BIOLASE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36385 87-0442441 (State or other jurisdiction of incorporation) (Commission File No
February 21, 2024	EX-99.1	JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Stock, par value $0.001 per share, of BIOLASE, INC. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13G. February 21, 2024 LIND GLOBAL FUND II LP By: Lind Global Partners II LLC its Ge
February 21, 2024	SC 13G	BIOL / BIOLASE, Inc. / Lind Global Fund II LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* BIOLASE, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 090911702 (CUSIP Number) February 15, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu
February 15, 2024	424B1	7,795,000 Units Each Consisting of One Share of Common Stock, One Class A Warrant to Purchase One Share of Common Stock and One Class B Warrant to Purchase One Share of Common Stock 8,205,000 Pre-Funded Units Each Consisting of One Pre-Funded Warrant 424B1 Table of Contents Filed Pursuant to Rule 424(b)(1) Registration Number 333-276596 7,795,000 Units Each Consisting of One Share of Common Stock, One Class A Warrant to Purchase One Share of Common Stock and One Class B Warrant to Purchase One Share of Common Stock 8,205,000 Pre-Funded Units Each Consisting of One Pre-Funded Warrant to Purchase One Share of Common Stock, One Class A Warrant to Purchase One Share of Common Stock and One Class B Warrant to Purchase One Share of Common Stock 16,000,000 Shares of Common Stock Underlying the Class A Warrants 16,000,000 Shares of Common Stock Underlying the Class B Warrants 8,205,000 Shares of Common Stock Underlying the Pre-Funded Warrants BIOLASE, Inc.
February 15, 2024	EX-1.1	Placement Agency Agreement, dated February 13, 2024, by and among BIOLASE, Inc., Lake Street Capital Markets, LLC and Maxim Group LLC Exhibit 1.1 PLACEMENT AGENCY AGREEMENT February 13, 2024 BIOLASE, Inc. 27042 Towne Centre Drive, Suite 270 Lake Forest, California 92610 Attn: John R. Beaver, President and Chief Executive Officer Dear Mr. Beaver: This letter agreement (the “Agreement”) constitutes the agreement between Lake Street Capital Markets, LLC (“Lake Street”) and Maxim Group LLC (“Maxim”), as placement agents (each a “Pla
February 15, 2024	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 12, 2024 BIOLASE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36385 87-0442441 (State or other jurisdiction of incorporation) (Commission File No
February 15, 2024	EX-99.2	BIOLASE, Inc. Announces Closing of $7.0 Million Public Offering Exhibit 99.2 BIOLASE, Inc. Announces Closing of $7.0 Million Public Offering LAKE FOREST, Calif., February 15, 2024 /PRNewswire/ — BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced the closing of its public offering of 16,000,000 units, with each unit consisting of one share of common stock (or one pre-funded warrant to purchase one share of common stock), one Class
February 15, 2024	EX-4.5	Form of Warrant issued to Investor Exhibit 4.5 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
February 15, 2024	EX-4.1	Form of Pre-Funded Warrant to Purchase Common Stock Exhibit 4.1 FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT BIOLASE, INC. Warrant Shares: [] Initial Exercise Date: February 15, 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
February 15, 2024	EX-99.1	BIOLASE, Inc. Announces Pricing of $7.0 Million Public Offering Exhibit 99.1 BIOLASE, Inc. Announces Pricing of $7.0 Million Public Offering LAKE FOREST, Calif., February 13, 2024 /PRNewswire/ — BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced the pricing of its public offering of 16,000,000 units, with each unit consisting of one share of common stock (or one pre-funded warrant to purchase one share of common stock), one Class
February 15, 2024	EX-4.3	Form of Class B Warrant to Purchase Common Stock Exhibit 4.3 FORM OF CLASS B WARRANT TO PURCHASE COMMON STOCK BIOLASE, INC. Warrant Shares: [] Issuance Date: February 15, 2024 THIS CLASS B WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received by BIOLASE, Inc., a Delaware corporation (the “Company”), or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the condit
February 15, 2024	EX-10.2	Consent and Waiver, dated February 12, 2024, by and between BIOLASE, Inc. and the Investor named therein Exhibit 10.2 CONSENT AND WAIVER This Consent and Waiver (the “Agreement”), dated as of February 12, 2024, is entered into by and between BIOLASE, Inc. (the “Company”) and Anson Investments Master Fund LP (the “Investor”). WHEREAS, pursuant to that certain Securities Purchase Agreement, dated December 6, 2023, by and between the Company and the Investor (the “Purchase Agreement”), the Company agree
February 15, 2024	EX-4.2	Form of Class A Warrant to Purchase Common Stock Exhibit 4.2 CLASS A WARRANT TO PURCHASE COMMON STOCK BIOLASE, INC. Warrant Shares: [•] Initial Exercise Date: February 15, 2024 Issue Date: February 15, 2024 THIS CLASS A WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, [•] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set fort
February 15, 2024	EX-10.1	Form of Securities Purchase Agreement, dated as of dated February 13, 2024, by and among BIOLASE, Inc. and the investors parties thereto Exhibit 10.1 FORM OF SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 13, 2024, between BIOLASE, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condition
February 15, 2024	EX-4.4	Warrant Agency Agreement, dated February 15, 2024, by and among BIOLASE, Inc., Computershare Inc., a Delaware corporation, and its affiliate, Computershare Trust Company, N.A., a federal trust company Exhibit 4.4 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT (this “Warrant Agency Agreement”) dated as of February 15, 2024 (the “Issuance Date”) between BIOLASE, Inc., a company incorporated under the laws of the State of Delaware (the “Company”), and Computershare Inc., a Delaware corporation (“Computershare”), and its affiliate Computershare Trust Company, N.A., a federally chartered trust co
February 14, 2024	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 d764424dex991.htm EX-99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.001 par value, of Biolase, Inc. a Delaware corporation, and f
February 14, 2024	SC 13G	BIOL / BIOLASE, Inc. / Anson Funds Management LP - SC 13G Passive Investment SC 13G 1 d764424dsc13g.htm SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) (Amendment No. ) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) BIOLASE, INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 0911702 (CUSIP Number) Decembe
February 14, 2024	SC 13G/A	US0909117022 / BIOLASE INC / LYTTON LAURENCE W Passive Investment SC 13G/A 1 biol13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Biolase, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 090911702 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to
February 13, 2024	SC 13G/A	US0909117022 / BIOLASE INC / Lind Global Fund II LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* BIOLASE, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 090911702 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule purs
February 13, 2024	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 exhibit99-1.htm JOINT FILING AGREEMENT BY AND AMONG THE REPORTING PERSONS Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Stock, par value $0.001 per share, of BIOLASE, INC., shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule
February 9, 2024	CORRESP	BIOLASE, Inc. 27042 Towne Centre Drive, Suite 270 Lake Forest, California 92610 (949) 361-1200 BIOLASE, Inc. 27042 Towne Centre Drive, Suite 270 Lake Forest, California 92610 (949) 361-1200 February 9, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jessica Ansart Re: BIOLASE, Inc. Registration Statement on Form S-1, as amended File No: 333-276596 Request for Acceleration of Effectiveness La
February 9, 2024	EX-4.8	Form of Class B Warrant to Purchase Common Stock EX-4.8 Exhibit 4.8 CLASS B WARRANT TO PURCHASE COMMON STOCK BIOLASE, INC. Warrant Shares: Issuance Date: , 2024 THIS CLASS B WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received by the Company, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or afte
February 9, 2024	S-1/A	As filed with the Securities and Exchange Commission on February 9, 2024 S-1/A Table of Contents As filed with the Securities and Exchange Commission on February 9, 2024 Registration No.
February 9, 2024	EX-4.7	Form of Class A Warrant to Purchase Common Stock EX-4.7 Exhibit 4.7 CLASS A WARRANT TO PURCHASE COMMON STOCK BIOLASE, INC. Warrant Shares: [•] Initial Exercise Date: [•], 2024 Issue Date: [•], 2024 THIS CLASS A WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, [•] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any
February 9, 2024	EX-10.25	Form of Securities Purchase Agreement EX-10.25 Exhibit 10.25 FORM OF SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of [], 2024, between BIOLASE, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditio
February 7, 2024	EX-10.25	Form of Securities Purchase Agreement Exhibit 10.25 FORM OF SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of [], 2024, between BIOLASE, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set fo
February 7, 2024	EX-4.7	Form of Class A Warrant to Purchase Common Stock Exhibit 4.7 CLASS A WARRANT TO PURCHASE COMMON STOCK BIOLASE, INC. Warrant Shares: [•] Initial Exercise Date: [•], 2024 Issue Date: [•], 2024 THIS CLASS A WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, [•] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time o
February 7, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) BIOLASE, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price(1)(2) Fee Rate Amount of Registration Fee(3) Carry
February 7, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 7, 2024 BIOLASE, INC. (E UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 7, 2024 BIOLASE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36385 87-0442441 (State or other jurisdiction of incorporation) (Commission File No.
February 7, 2024	EX-4.8	Form of Class B Warrant to Purchase Common Stock Exhibit 4.8 CLASS B WARRANT TO PURCHASE COMMON STOCK BIOLASE, INC. Warrant Shares: Issuance Date: , 2024 THIS CLASS B WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received by the Company, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the S
February 7, 2024	EX-1.3	Form of Placement Agency Agreement by and among the Company, Lake Street Capital Markets, LLC and Maxim Group LLC Exhibit 1.3 FORM OF PLACEMENT AGENCY AGREEMENT [ ], 2024 BIOLASE, Inc. 27042 Towne Centre Drive, Suite 270 Lake Forest, California 92610 Attn: John R. Beaver, President and Chief Executive Officer Dear Mr. Beaver: This letter agreement (the “Agreement”) constitutes the agreement between Lake Street Capital Markets, LLC (“Lake Street”) and Maxim Group LLC (“Maxim”), as placement agents (each a “P
February 7, 2024	S-1/A	As filed with the Securities and Exchange Commission on February 7, 2024 Table of Contents As filed with the Securities and Exchange Commission on February 7, 2024 Registration No.
February 7, 2024	EX-4.9	Form of Warrant Agency Agreement by and among BIOLASE, Inc., Computershare Inc., a Delaware corporation, and its affiliate, Computershare Trust Company, N.A., a federal trust company Exhibit 4.9 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT (this “Warrant Agency Agreement”) dated as of [ ], 2024 (the “Issuance Date”) between BIOLASE, Inc., a company incorporated under the laws of the State of Delaware (the “Company”), and Computershare Inc., a Delaware corporation (“Computershare”), and its affiliate Computershare Trust Company, N.A., a federally chartered trust compan
January 31, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) BIOLASE, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price(1)(2) Fee Rate Amount of Registration Fee(3) Carry
January 31, 2024	EX-4.7	Form of Warrant to Purchase Common Stock EX-4.7 Exhibit 4.7 FORM OF COMMON STOCK PURCHASE WARRANT BIOLASE, INC. Warrant Shares: [ ] Initial Exercise Date: [ ], 2024 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date
January 31, 2024	EX-1.3	Form of Placement Agency Agreement by and among the Company, Lake Street Capital Markets, LLC and Maxim Group LLC Exhibit 1.3 FORM OF PLACEMENT AGENCY AGREEMENT [ ], 2024 BIOLASE, Inc. 27042 Towne Centre Drive, Suite 270 Lake Forest, California 92610 Attn: John R. Beaver, President and Chief Executive Officer Dear Mr. Beaver: This letter agreement (the “Agreement”) constitutes the agreement between Lake Street Capital Markets, LLC (“Lake Street”) and Maxim Group LLC (“Maxim”), as placement agents (each a “P
January 31, 2024	S-1/A	As filed with the Securities and Exchange Commission on January 30, 2024 S-1/A Table of Contents As filed with the Securities and Exchange Commission on January 30, 2024 Registration No.
January 31, 2024	EX-4.6	Form of Pre-Funded Warrant to Purchase Common Stock EX-4.6 Exhibit 4.6 FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT BIOLASE, INC. Warrant Shares: [ ] Initial Exercise Date: [ ], 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on
January 31, 2024	EX-10.25	Form of Securities Purchase Agreement Exhibit 10.25 FORM OF SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of [], 2024, between BIOLASE, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set fo
January 31, 2024	EX-4.8	Form of Warrant Agency Agreement by and among BIOLASE, Inc., Computershare Inc., a Delaware corporation, and its affiliate, Computershare Trust Company, N.A., a federal trust company Exhibit 4.8 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT (this “Warrant Agency Agreement”) dated as of [ ], 2024 (the “Issuance Date”) between BIOLASE, Inc., a company incorporated under the laws of the State of Delaware (the “Company”), and Computershare Inc., a Delaware corporation (“Computershare”), and its affiliate Computershare Trust Company, N.A., a federally chartered trust compan
January 29, 2024	EX-99.1	BIOLASE REPORTS UNAUDITED REVENUE GROWTH FOR FULL YEAR 2023 AND PROVIDES OUTLOOK FOR FULL YEAR 2024 Expects Continued Revenue Growth in 2024 and Takes Steps to Further Improve Operating Efficiency as the Company Pursues Profitability Goals Exhibit 99.1 BIOLASE REPORTS UNAUDITED REVENUE GROWTH FOR FULL YEAR 2023 AND PROVIDES OUTLOOK FOR FULL YEAR 2024 Expects Continued Revenue Growth in 2024 and Takes Steps to Further Improve Operating Efficiency as the Company Pursues Profitability Goals LAKE FOREST, Calif., January 29, 2024 – BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced preliminary unaudited revenue r
January 29, 2024	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 29, 2024 BIOLASE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36385 87-0442441 (State or other jurisdiction of incorporation) (Commission File No.
January 24, 2024	S-8	As filed with the Securities and Exchange Commission on January 24, 2024 As filed with the Securities and Exchange Commission on January 24, 2024 Registration No.
January 24, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) BIOLASE, Inc. (Exact Name of Registrant as Specified in its Charter) Table1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) (2) Proposed Maximum Offering Price per Unit(3) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par value $0.
January 19, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107.1 Calculation of Filing Fee Tables FORM S-1 (Form Type) BIOLASE, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price(1)(2) Fee Rate Amount of Registration Fee(3) Carry Forward Form
January 19, 2024	S-1	As filed with the Securities and Exchange Commission on January 19, 2024 S-1 Table of Contents As filed with the Securities and Exchange Commission on January 19, 2024 Registration No.
December 29, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 29, 2023 BIOLASE, INC. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 29, 2023 BIOLASE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36385 87-0442441 (State or other jurisdiction of incorporation) (Commission File No
December 26, 2023	S-1	As filed with the Securities and Exchange Commission on December 26, 2023 S-1 Table of Contents As filed with the Securities and Exchange Commission on December 26, 2023 Registration No.
December 26, 2023	EX-FILING FEES	Filing Fee Table EX107 Calculation of Filing Fee Tables Form S-1 (Form Type) BIOLASE, Inc. (Exact Name of Registrant as Specified in its Charter) Table1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1)(3) Proposed Maximum Offering Price per Unit(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par value $0.001 per
December 8, 2023	424B5	331,000 Shares of Common Stock Pre-Funded Warrants to Purchase 779,940 Shares of Common Stock 779,940 Shares of Common Stock Underlying the Pre-Funded Warrants BIOLASE, Inc. Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-266852 Prospectus Supplement (to Prospectus dated August 24, 2022) 331,000 Shares of Common Stock Pre-Funded Warrants to Purchase 779,940 Shares of Common Stock 779,940 Shares of Common Stock Underlying the Pre-Funded Warrants BIOLASE, Inc. We are offering 331,000 shares of our common stock, $0.001 par value per share (the “Co
December 8, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 6, 2023 BIOLASE, INC. (E UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 6, 2023 BIOLASE, INC. (Exact name of registrant as specified in its charter) Delaware 001-38116 87-0442441 (State or other jurisdiction of incorporation) (Commission File No.
December 8, 2023	EX-1.1	Placement Agency Agreement, dated December 6, 2023, by and between the Company and Maxim Group LLC Exhibit 1.1 PLACEMENT AGENCY AGREEMENT December 6, 2023 Mr. John R. Beaver Chief Financial Officer BIOLASE, Inc. 27042 Towne Centre Drive, Suite 270 Lake Forest, CA 92610 Dear Mr. Beaver: This letter agreement (the “Agreement”) constitutes the agreement between Maxim Group LLC (“Maxim” or the “Placement Agent”) and BIOLASE, Inc., a company incorporated under the laws of the State of Delaware (the
December 8, 2023	EX-4.2	Form of Warrant to Purchase Common Stock Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
December 8, 2023	EX-99.1	BIOLASE, INC. ANNOUNCES PRICING OF $1.4 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES Exhibit 99.1 BIOLASE, INC. ANNOUNCES PRICING OF $1.4 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES LAKE FOREST, Calif., Dec. 6, 2023 /PRNewswire/ — BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced today that it has entered into a securities purchase agreement with a single institutional investor to purchase approximately $1.4 million of its c
December 8, 2023	EX-4.1	Form of Pre-Funded Warrant to Purchase Common Stock Exhibit 4.1 FORM OF PREFUNDED COMMON STOCK PURCHASE WARRANT BIOLASE, INC. Warrant Shares: Issue Date: [], 2023 THIS PREFUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issue Date (the “Init
December 8, 2023	EX-10.1	Form of Securities Purchase Agreement, dated as of December 6, 2023, by and among the Company and the investors party thereto Exhibit 10.1 FORM OF SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 6, 2023, between BIOLASE, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions
November 17, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 14, 2023 BIOLASE, INC. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 14, 2023 BIOLASE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36385 87-0442441 (State or other jurisdiction of incorporation) (Commission File No
November 9, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36385 BIOLASE, INC.
November 9, 2023	EX-99.1	BIOLASE REPORTS THIRD QUARTER FINANCIAL RESULTS; COMPANY BENEFITTING FROM STRATEGIC ACTIONS TAKEN TO STREAMLINE OPERATIONS AND GAIN GREATER OPERATIONAL EFFICIENCIES Exhibit 99.1 BIOLASE REPORTS THIRD QUARTER FINANCIAL RESULTS; COMPANY BENEFITTING FROM STRATEGIC ACTIONS TAKEN TO STREAMLINE OPERATIONS AND GAIN GREATER OPERATIONAL EFFICIENCIES LAKE FOREST, Calif., November 9, 2023 – BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced its financial results for the third quarter ended September 30, 2023. Third Quarter Financial Summar
November 9, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 BIOLASE, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36385 87-0442441 (State or Other Jurisdiction of Incorporation) (Commission File Num
October 10, 2023	SC 13G/A	BIOL / Biolase Inc / Krefta Edson Roberto - FORM 13-G/A Passive Investment Form 13-G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 1 Under the Securities Exchange Act of 1934 (Amendment No. )* Biolase, Inc. (Name of Issuer) Common Stock, $.0001 par value per share (Title of Class of Securities) 0911702 (CUSIP Number) October 6, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box t
September 18, 2023	EX-4.1	Warrant Agency Agreement dated September 18, 2023, by and among BIOLASE, Inc., Computershare Inc., a Delaware corporation, and its affiliate, Computershare Trust Company, N.A., a federal trust company Exhibit 4.1 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT (this “Warrant Agency Agreement”) dated as of September 18, 2023 (the “Issuance Date”) between BIOLASE, Inc., a company incorporated under the laws of the State of Delaware (the “Company”), and Computershare Inc., a Delaware corporation (“Computershare”), and its affiliate Computershare Trust Company, N.A., a federally chartered trust c
September 18, 2023	EX-99.1	BIOLASE Inc. Announces Pricing of $4.5 Million Underwritten Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants Exhibit 99.1 BIOLASE Inc. Announces Pricing of $4.5 Million Underwritten Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants Lake Forest, Calif., September 13, 2023 – BIOLASE, Inc. (NASDAQ: BIOL) (“BIOLASE” or the “Company”), a global leader in dental lasers, today announced the pricing of an underwritten public offering of 75,000 units (the “Units”), with each Unit con
September 18, 2023	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 13, 2023 BIOLASE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36385 87-0442441 (State or other jurisdiction of incorporation) (Commission File N
September 18, 2023	EX-1.1	Underwriting Agreement dated September 13, 2023 by and among BIOLASE, Inc., Lake Street Capital Markets, LLC and Maxim Group LLC, as representatives of the several underwriters named therein Exhibit 1.1 BIOLASE, INC. UNDERWRITING AGREEMENT September 13, 2023 Lake Street Capital Markets, LLC 920 Second Avenue South, Suite 700 Minneapolis, Minnesota 55402 and Maxim Group LLC 405 Lexington Avenue New York, New York 10174 As Representatives of the Several underwriters, if any, named in Schedule I hereto Ladies and Gentlemen: The undersigned, BIOLASE, INC., a company incorporated under the
September 18, 2023	EX-99.2	BIOLASE Inc. Announces Closing of $4.5 Million Underwritten Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants Exhibit 99.2 BIOLASE Inc. Announces Closing of $4.5 Million Underwritten Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants Lake Forest, Calif., September 18, 2023 – BIOLASE, Inc. (NASDAQ: BIOL) (“BIOLASE” or the “Company”), a global leader in dental lasers, today announced the closing of its previously announced underwritten public offering of 75,000 units (the “Units
September 18, 2023	EX-4.2	Form of Warrant to Purchase Shares of Series J Convertible Preferred Stock Exhibit 4.2 FORM OF PREFERRED STOCK PURCHASE WARRANT BIOLASE, INC. Preferred Warrant Shares: Initial Exercise Date: September 18, 2023 Issuance Date: September 18, 2023 THIS PREFERRED STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value of $0.001 received by the Company, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditi
September 18, 2023	EX-3.1	Certificate of Designation of the Series J Convertible Redeemable Preferred Stock Exhibit 3.1 CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES J CONVERTIBLE REDEEMABLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW The undersigned, John R. Beaver, does hereby certify that: 1. He is the Chief Executive Officer of BIOLASE, Inc., a Delaware corporation (the “Corporation”). 2. The Corporation is authorized to issue 1,000,0
September 15, 2023	424B1	75,000 Units Consisting of 75,000 Shares of Series J Convertible Preferred Stock with a Liquidation Preference of $100.00 and 75,000 Warrants to Purchase 37,500 Shares of Series J Convertible Preferred Stock 37,500 Shares of Series J Convertible Pref Table of Contents Filed Pursuant to Rule 424(b)(1) Registration Numbers 333-273372 and 333-274504 PROSPECTUS 75,000 Units Consisting of 75,000 Shares of Series J Convertible Preferred Stock with a Liquidation Preference of $100.
September 15, 2023	424B1	75,000 Units Consisting of 75,000 Shares of Series J Convertible Preferred Stock with a Liquidation Preference of $100.00 and 75,000 Warrants to Purchase 37,500 Shares of Series J Convertible Preferred Stock 37,500 Shares of Series J Convertible Pref Table of Contents Filed Pursuant to Rule 424(b)(1) Registration Numbers 333-273372 and 333-274504 PROSPECTUS 75,000 Units Consisting of 75,000 Shares of Series J Convertible Preferred Stock with a Liquidation Preference of $100.
September 14, 2023	POS EX	As filed with the Securities and Exchange Commission on September 14, 2023 POS EX As filed with the Securities and Exchange Commission on September 14, 2023 Registration No.
September 13, 2023	EX-FILING FEES	Filing Fee Table EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) BIOLASE, INC.
September 13, 2023	S-1MEF	As filed with the Securities and Exchange Commission on September 13, 2023 As filed with the Securities and Exchange Commission on September 13, 2023 Registration No.
September 12, 2023	SC 13G	BIOL / Biolase Inc / Krefta Edson Roberto - FORM 13-G Passive Investment Form 13-G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Biolase, Inc. (Name of Issuer) Common Stock, $.0001 par value per share (Title of Class of Securities) 0911702 (CUSIP Number) 9/11/2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu
September 12, 2023	CORRESP	BIOLASE, Inc. 27042 Towne Centre Drive, Suite 270 Lake Forest, California 92610 (949) 361-1200 BIOLASE, Inc. 27042 Towne Centre Drive, Suite 270 Lake Forest, California 92610 (949) 361-1200 September 12, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jane Park Re: BIOLASE, Inc. Registration Statement on Form S-1, as amended File No: 333-273372 Request for Acceleration of Effectiveness Ladie
September 12, 2023	CORRESP	[Signature Page to Follow] September 12, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: BIOLASE, Inc. Registration Statement on Form S-1, as amended File No. 333-273372 Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the
September 11, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) BIOLASE, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price (1)(2) Fee Rate Amount of Registration Fee Newly Registered Se
September 11, 2023	S-1/A	As filed with the Securities and Exchange Commission on September 11, 2023 S-1/A Table of Contents As filed with the Securities and Exchange Commission on September 11, 2023 Registration No.
September 8, 2023	CORRESP	BIOLASE, Inc. 27042 Towne Centre Drive, Suite 270 Lake Forest, California 92610 (949) 361-1200 BIOLASE, Inc. 27042 Towne Centre Drive, Suite 270 Lake Forest, California 92610 (949) 361-1200 September 8, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention Jane Park Re: BIOLASE, Inc. Registration Statement on Form S-1, as amended File No: 333-273372 Withdrawal of Request for Acceleration of Effecti
September 8, 2023	CORRESP	[Signature Page to Follow] September 8, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Biolase, Inc. Registration Statement on Form S-1, as amended File 333-273372 Withdrawal of Request for Acceleration of Effective Date Ladies and Gentlemen: Reference is made to our letter, filed as correspondence via EDGAR on September 6, 2023, in which
September 6, 2023	CORRESP	BIOLASE, Inc. 27042 Towne Centre Drive, Suite 270 Lake Forest, California 92610 (949) 361-1200 BIOLASE, Inc. 27042 Towne Centre Drive, Suite 270 Lake Forest, California 92610 (949) 361-1200 September 6, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: BIOLASE, Inc. Registration Statement on Form S-1, as amended File No: 333-273372 Request for Acceleration Ladies and Gentlemen: BIOLASE, Inc. (the “Re
September 6, 2023	CORRESP	[Signature Page to Follow] September 6, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Biolase, Inc. Registration Statement on Form S-1, as amended File 333-273372 Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Sec
September 5, 2023	S-1/A	As filed with the Securities and Exchange Commission on September 1, 2023 S-1/A Table of Contents As filed with the Securities and Exchange Commission on September 1, 2023 Registration No.
August 30, 2023	EX-1.1	Form of Underwriting Agreement EX-1.1 Exhibit 1.1 BIOLASE, INC. FORM OF UNDERWRITING AGREEMENT [●], 2023 Lake Street Capital Markets, LLC 920 Second Avenue South, Suite 700 Minneapolis, Minnesota 55402 and Maxim Group LLC 405 Lexington Avenue New York, New York 10174 As Representatives of the Several underwriters, if any, named in Schedule I hereto Ladies and Gentlemen: The undersigned, BIOLASE, INC., a company incorporated und
August 30, 2023	EX-4.2	Form of Warrant to Purchase Series J Convertible Redeemable Preferred Stock EX-4.2 Exhibit 4.2 FORM OF PREFERRED STOCK PURCHASE WARRANT BIOLASE, INC. Preferred Warrant Shares: Initial Exercise Date: , 2023 Issuance Date: , 2023 THIS PREFERRED STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value of $0.001 received by the Company, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter s
August 30, 2023	EX-4.3	Form of Warrant Agency Agreement EX-4.3 Exhibit 4.3 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT (this “Warrant Agency Agreement”) dated as of [], 2023 (the “Issuance Date”) between BIOLASE, Inc., a company incorporated under the laws of the State of Delaware (the “Company”), and Computershare Inc., a Delaware corporation (“Computershare”), and its affiliate Computershare Trust Company, N.A., a federally chartered trust comp
August 30, 2023	EX-FILING FEES	Filing Fee Table EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) BIOLASE, INC.
August 30, 2023	EX-3.(1)(13)	Form of Certificate of Designation of the Series J Convertible Redeemable Preferred Stock EX-3.1.13 Exhibit 3.1.13 CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES J CONVERTIBLE REDEEMABLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW The undersigned, John R. Beaver, does hereby certify that: 1. He is the Chief Executive Officer of BIOLASE, Inc., a Delaware corporation (the “Corporation”). 2. The Corporation is authorized to
August 30, 2023	S-1/A	As filed with the Securities and Exchange Commission on August 30, 2023 S-1/A Table of Contents As filed with the Securities and Exchange Commission on August 30, 2023 Registration No.
August 18, 2023	S-1/A	As filed with the Securities and Exchange Commission on August 17, 2023 S-1/A Table of Contents As filed with the Securities and Exchange Commission on August 17, 2023 Registration No.
August 15, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 14, 2023 BIOLASE, INC. (Ex UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 14, 2023 BIOLASE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36385 87-0442441 (State or other jurisdiction of incorporation) (Commission File No.)
August 14, 2023	EX-4.4	Form of Warrant Agency Agreement Exhibit 4.4 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT (this “Warrant Agency Agreement”) dated as of [], 2023 (the “Issuance Date”) between BIOLASE, Inc., a company incorporated under the laws of the State of Delaware (the “Company”), and Computershare Inc., a Delaware corporation (“Computershare”), and its affiliate Computershare Trust Company, N.A., a federally chartered trust company (to
August 14, 2023	EX-10.24	Form of Securities Purchase Agreement to be entered into in this Offering Exhibit 10.24 FORM OF SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of [], 2023, between BIOLASE, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set fo
August 14, 2023	S-1/A	As filed with the Securities and Exchange Commission on August 11, 2023 Table of Contents As filed with the Securities and Exchange Commission on August 11, 2023 Registration No.
August 14, 2023	EX-1.1	Form of Placement Agency Agreement EX-1.1 Exhibit 1.1 PLACEMENT AGENCY AGREEMENT [ ], 2023 BIOLASE, Inc. 27042 Towne Centre Drive, Suite 270 Lake Forest, California 92610 Attn: John R. Beaver, President and Chief Executive Officer Dear Mr. Beaver: This letter agreement (the “Agreement”) constitutes the agreement between Lake Street Capital Markets, LLC (“Lake Street”) and Maxim Group LLC (“Maxim”), as placement agents (each a “Plac
August 14, 2023	EX-4.2	Form of Warrant EX-4.2 Exhibit 4.2 COMMON STOCK PURCHASE WARRANT BIOLASE, INC. Warrant Shares: [] Initial Exercise Date: [], 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Ex
August 14, 2023	EX-4.3	Form of Pre-Funded Warrant EX-4.3 Exhibit 4.3 PRE-FUNDED COMMON STOCK PURCHASE WARRANT BIOLASE, INC. Warrant Shares: [] Initial Exercise Date: [], 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date h
August 10, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 BIOLASE, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36385 87-0442441 (State or Other Jurisdiction of Incorporation) (Commission File Numb
August 10, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36385 BIOLASE, INC. (Exac
August 10, 2023	EX-10.2	Change in Control Agreement, dated August 9, 2023 by and between Biolase, Inc. and Steven Sandor Exhibit 10.2 To: Steven Sandor From: John R. Beaver, President and Chief Executive Officer Date: August 9, 2023 Re: Severance Benefits Payable on Change of Control In consideration of your employment by Biolase, Inc. (the “Company” or “Biolase”) and the compensation now and hereafter paid to you, this memorandum (hereinafter the “Agreement”) amends and modifies the terms of any employment agreemen
August 10, 2023	EX-99.1	BIOLASE REPORTS RECORD CONSUMABLE SALES AS TOTAL SECOND QUARTER REVENUE INCREASES 17% YEAR OVER YEAR Continues to Experience Positive Momentum and Expects to Achieve Improved Net Income and Positive Adjusted EBITDA for the Second Half of 2023 Exhibit 99.1 BIOLASE REPORTS RECORD CONSUMABLE SALES AS TOTAL SECOND QUARTER REVENUE INCREASES 17% YEAR OVER YEAR Continues to Experience Positive Momentum and Expects to Achieve Improved Net Income and Positive Adjusted EBITDA for the Second Half of 2023 LAKE FOREST, Calif., August 10, 2023 – BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced its financial results f
August 10, 2023	EX-10.1	Change in Control Agreement, dated August 9, 2023 by and between Biolase, Inc. and Jennifer Bright Exhibit 10.1 To: Jennifer Bright From: John R. Beaver, President and Chief Executive Officer Date: August 9, 2023 Re: Severance Benefits Payable on Change of Control In consideration of your employment by Biolase, Inc. (the “Company” or “Biolase”) and the compensation now and hereafter paid to you, this memorandum (hereinafter the “Agreement”) amends and modifies the terms of any employment agreem
July 26, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 20, 2023 BIOLASE, INC. (Exac UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 20, 2023 BIOLASE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36385 87-0442441 (State or other jurisdiction of incorporation) (Commission File No.) (
July 26, 2023	EX-3.1	Seventh Amendment to Restated Certificate of Incorporation EX-3.1 Exhibit 3.1 SEVENTH AMENDMENT TO RESTATED CERTIFICATE OF INCORPORATION OF BIOLASE, INC. BIOLASE, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, hereby certifies as follows: 1. This Certificate of Amendment amends the provisions of the Corporation’s Restated Certificate of Incorporation, as amended a
July 26, 2023	EX-99.1	BIOLASE ANNOUNCES 1-FOR-100 REVERSE STOCK SPLIT COMMON STOCK WILL BEGIN TRADING ON SPLIT-ADJUSTED BASIS ON JULY 28, 2023 EX-99.1 Exhibit 99.1 BIOLASE ANNOUNCES 1-FOR-100 REVERSE STOCK SPLIT COMMON STOCK WILL BEGIN TRADING ON SPLIT-ADJUSTED BASIS ON JULY 28, 2023 Lake Forest, Calif., July 26, 2023 – BIOLASE, Inc. (NASDAQ: BIOL) (“BIOLASE” or the “Company”), a global leader in dental lasers, today announced that it held a special meeting of its stockholders on July 20, 2023 where the Company’s stockholders granted the
July 21, 2023	EX-FILING FEES	Filing Fee Table EX-FILING FEES Exhibit 107.1 Calculation of Filing Fee Tables FORM S-1 (Form Type) BIOLASE, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price(1)(2) Fee Rate Amount of Registration Fee(3) Car
July 21, 2023	S-1	Power of Attorney S-1 Table of Contents As filed with the Securities and Exchange Commission on July 21, 2023 Registration No.
June 23, 2023	EX-16.1	Letter from BDO USA, LLP, dated June 22, 2023 addressed to the U.S. Securities and Exchange Commission EX-16.1 Exhibit 16.1 June 22, 2023 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 We have been furnished with a copy of the response to Item 4.01 of Form 8-K for the event that occurred on June 21, 2023, to be filed by our former client, Biolase, Inc. We agree with the statements made in response to that Item insofar as they relate to our Firm. Very truly yours, /s/ BD
June 23, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 21, 2023 BIOLASE, INC. (Exac UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 21, 2023 BIOLASE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36385 87-0442441 (State or other jurisdiction of incorporation) (Commission File No.) (
June 21, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under § 240.
June 13, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 8, 2023 BIOLASE, INC. (Exact UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 8, 2023 BIOLASE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36385 87-0442441 (State or other jurisdiction of incorporation) (Commission File No.) (I
June 7, 2023	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under § 240.
June 6, 2023	EX-99.1	BIOLASE ANNOUNCES DISTRIBUTION OF SERIES I PREFERRED STOCK TO HOLDERS OF ITS COMMON STOCK EX-99.1 Exhibit 99.1 BIOLASE ANNOUNCES DISTRIBUTION OF SERIES I PREFERRED STOCK TO HOLDERS OF ITS COMMON STOCK Lake Forest, Calif., June 5, 2023 – BIOLASE, Inc. (NASDAQ: BIOL) (“BIOLASE” or the “Company”), a global leader in dental lasers, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly-designated Series I Preferred Stock, par value $0.001
June 6, 2023	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2023 BIOLASE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36385 87-0442441 (State or other jurisdiction of incorporation) (Commission File Number)
June 6, 2023	EX-3.1	Certificate of Designation of the Series I Preferred Stock of the Company, dated June 5, 2023 EX-3.1 Exhibit 3.1 BIOLASE, INC. CERTIFICATE OF DESIGNATION OF SERIES I PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of BIOLASE, Inc., a Delaware corporation (the “Corporation”), that the following resolution was duly adopted by the board of directors of the Corporation (the “Board of Directors”), in
June 6, 2023	8-A12G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOLASE, INC. (Exact name of registrant as sp 8-A12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOLASE, INC. (Exact name of registrant as specified in its charter) Delaware 87-0442441 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) 27
May 26, 2023	EX-3.1	Certificate of Designation of Preferences, Rights and Limitations of Series H Convertible Redeemable Preferred Stock, dated May 25, 2023 EX-3.1 Exhibit 3.1 CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES H CONVERTIBLE REDEEMABLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW The undersigned, John R. Beaver, does hereby certify that: 1. He is the Chief Executive Officer of BIOLASE, Inc., a Delaware corporation (the “Corporation”). 2. The Corporation is authorized to issue
May 26, 2023	EX-1.1	Underwriting Agreement, dated May 24, 2023, by and between BIOLASE, Inc. and Lake Street Capital Markets, LLC, as representative of the several underwriters named therein EX-1.1 Exhibit 1.1 BIOLASE, INC. FORM OF UNDERWRITING AGREEMENT May 24, 2023 Lake Street Capital Markets, LLC 920 Second Avenue South, Suite 700 Minneapolis, Minnesota 55402 As Representative of the Several underwriters, if any, named in Schedule I hereto Ladies and Gentlemen: The undersigned, BIOLASE, INC., a company incorporated under the laws of Delaware (collectively with its subsidiaries and
May 26, 2023	EX-4.2	Form of Warrant to Purchase Series H Convertible Preferred Stock EX-4.2 Exhibit 4.2 FORM OF PREFERRED STOCK PURCHASE WARRANT BIOLASE, INC. Preferred Warrant Shares: Initial Exercise Date: May 26, 2023 Issuance Date: May 26, 2023 THIS PREFERRED STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value of $0.001 received by the Company, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions h
May 26, 2023	EX-4.1	Computershare Inc., a Delaware corporation, and its affiliate, Computershare Trust Company, N.A., a federal trust company EX-4.1 4 d469757dex41.htm EX-4.1 Exhibit 4.1 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT (this “Warrant Agency Agreement”) dated as of May 26, 2023 (the “Issuance Date”) between BIOLASE, Inc., a company incorporated under the laws of the State of Delaware (the “Company”), and Computershare Inc., a Delaware corporation (“Computershare”), and its affiliate Computershare Trust Company, N.A., a
May 26, 2023	EX-99.2	BIOLASE Inc. Announces Closing of $4.5 Million Underwritten Public Offering of Series H Convertible Redeemable Preferred Stock and Warrants EX-99.2 Exhibit 99.2 BIOLASE Inc. Announces Closing of $4.5 Million Underwritten Public Offering of Series H Convertible Redeemable Preferred Stock and Warrants Lake Forest, Calif., May 26, 2023 – BIOLASE, Inc. (NASDAQ: BIOL) (“BIOLASE” or the “Company”), a global leader in dental lasers, today announced the closing of its previously announced underwritten public offering of 175,000 units (the “Un
May 26, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 24, 2023 BIOLASE, INC. (Exact UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 24, 2023 BIOLASE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36385 87-0442441 (State or other jurisdiction of incorporation) (Commission File No.) (I
May 26, 2023	EX-99.1	BIOLASE Inc. Announces Pricing of $4.5 Million Underwritten Public Offering of Series H Convertible Redeemable Preferred Stock and Warrants EX-99.1 Exhibit 99.1 BIOLASE Inc. Announces Pricing of $4.5 Million Underwritten Public Offering of Series H Convertible Redeemable Preferred Stock and Warrants Lake Forest, Calif., May 24, 2023 – BIOLASE, Inc. (NASDAQ: BIOL) (“BIOLASE” or the “Company”), a global leader in dental lasers, today announced the pricing of an underwritten public offering of 175,000 units (the “Units”), with each Unit
May 25, 2023	424B1	175,000 Units Each Unit Consisting of One Share of Series H Convertible Redeemable Preferred Stock with a Liquidation Preference of $50.00 and One Warrant to Purchase One-Half of One Share of Series H Convertible Redeemable Preferred Stock Shares of 424B1 Table of Contents Filed Pursuant to Rule 424(b)(1) Registration Number 333-271660 PROSPECTUS 175,000 Units Each Unit Consisting of One Share of Series H Convertible Redeemable Preferred Stock with a Liquidation Preference of $50.
May 24, 2023	EX-4.7	Form of Warrant to Purchase Series H Convertible Redeemable Preferred Stock EX-4.7 Exhibit 4.7 PREFERRED STOCK PURCHASE WARRANT BIOLASE, INC. Preferred Warrant Shares: Initial Exercise Date: , 2023 Issuance Date: , 2023 THIS PREFERRED STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value of $0.001 received by the Company, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth
May 24, 2023	S-1/A	As filed with the Securities and Exchange Commission on May 24, 2023 S-1/A Table of Contents As filed with the Securities and Exchange Commission on May 24, 2023 Registration No.
May 24, 2023	EX-FILING FEES	Filing Fee Table EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) BIOLASE, INC.
May 24, 2023	EX-1.1	Form of Underwriting Agreement Exhibit 1.1 BIOLASE, INC. FORM OF UNDERWRITING AGREEMENT May [], 2023 Lake Street Capital Markets, LLC 920 Second Avenue South, Suite 700 Minneapolis, Minnesota 55402 As Representative of the Several underwriters, if any, named in Schedule I hereto Ladies and Gentlemen: The undersigned, BIOLASE, INC., a company incorporated under the laws of Delaware (collectively with its subsidiaries and affilia
May 24, 2023	EX-3.3	Form of Certificate of Designation of Preferences, Rights and Limitations of Series H Convertible Redeemable Preferred Stock EX-3.3 Exhibit 3.3 CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES H CONVERTIBLE REDEEMABLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW The undersigned, John R. Beaver, does hereby certify that: 1. He is the Chief Executive Officer of BIOLASE, Inc., a Delaware corporation (the “Corporation”). 2. The Corporation is authorized to issue
May 22, 2023	EX-4.6	Form of Warrant Agency Agreement EX-4.6 Exhibit 4.6 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT (this “Warrant Agency Agreement”) dated as of [], 2023 (the “Issuance Date”) between BIOLASE, Inc., a company incorporated under the laws of the State of Delaware (the “Company”), and Computershare Inc., a Delaware corporation (“Computershare”), and its affiliate Computershare Trust Company, N.A., a federally chartered trust comp
May 22, 2023	S-1/A	As filed with the Securities and Exchange Commission on May 22, 2023 S-1/A Table of Contents As filed with the Securities and Exchange Commission on May 22, 2023 Registration No.
May 22, 2023	EX-1.1	Form of Underwriting Agreement EX-1.1 Exhibit 1.1 BIOLASE, INC. FORM OF UNDERWRITING AGREEMENT May [], 2023 Lake Street Capital Markets, LLC 920 Second Avenue South, Suite 700 Minneapolis, Minnesota 55402 As Representative of the Several underwriters, if any, named in Schedule I hereto Ladies and Gentlemen: The undersigned, BIOLASE, INC., a company incorporated under the laws of Delaware (collectively with its subsidiaries and
May 22, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) BIOLASE, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price (1)(2) Fee Rate Amount of Registration Fee Newly Registered Se
May 22, 2023	EX-4.7	Form of Warrant to Purchase Series H Convertible Redeemable Preferred Stock EX-4.7 Exhibit 4.7 PREFERRED STOCK PURCHASE WARRANT BIOLASE, INC. Preferred Warrant Shares: Initial Exercise Date: , 2023 Issuance Date: , 2023 THIS PREFERRED STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value of $0.001 received by the Company, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth
May 22, 2023	EX-3.3	Form of Certificate of Designation of Preferences, Rights and Limitations of Series H Convertible Redeemable Preferred Stock EX-3.3 Exhibit 3.3 CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES H CONVERTIBLE REDEEMABLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW The undersigned, John R. Beaver, does hereby certify that: 1. He is the Chief Executive Officer of BIOLASE, Inc., a Delaware corporation (the “Corporation”). 2. The Corporation is authorized to issue
May 19, 2023	CORRESP	BIOLASE, Inc. 27042 Towne Centre Drive, Suite 270 Lake Forest, California 92610 (949) 361-1200 CORRESP BIOLASE, Inc. 27042 Towne Centre Drive, Suite 270 Lake Forest, California 92610 (949) 361-1200 May 19, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: BIOLASE, Inc. Registration Statement on Form S-1, as amended File No: 333-271660 Request for Acceleration Ladies and Gentlemen: BIOLASE, Inc. (the
May 19, 2023	CORRESP	May 19, 2023 CORRESP May 19, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Biolase, Inc. Registration Statement on Form S-1, as amended File No. 333-271660 Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (t
May 18, 2023	S-1/A	As filed with the Securities and Exchange Commission on May 17, 2023 AMENDMENT NO. 1 TO FORM S-1 Table of Contents As filed with the Securities and Exchange Commission on May 17, 2023 Registration No. 333-271660 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIOLASE, INC. (Exact name of registrant as specified in its charter) Delaware 3843 87-0442441 (State
May 18, 2023	EX-4.6	Form of Certificate of Designation of Preferences, Rights and Limitations of Series H Convertible Redeemable Preferred Stock of the Registrant* Exhibit 4.6 CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES H CONVERTIBLE REDEEMABLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW The undersigned, John R. Beaver, does hereby certify that: 1. He is the Chief Executive Officer of BIOLASE, Inc., a Delaware corporation (the “Corporation”). 2. The Corporation is authorized to issue 1,000,0
May 18, 2023	EX-FILING FEES	Filing Fee Table EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) BIOLASE, INC.
May 18, 2023	EX-1.1	Form of Underwriting Agreement EX-1.1 Exhibit 1.1 BIOLASE, INC. FORM OF UNDERWRITING AGREEMENT May [], 2023 Lake Street Capital Markets, LLC 920 Second Avenue South, Suite 700 Minneapolis, Minnesota 55402 As Representative of the Several underwriters, if any, named in Schedule I hereto Ladies and Gentlemen: The undersigned, BIOLASE, INC., a company incorporated under the laws of Delaware (collectively with its subsidiaries and
May 18, 2023	EX-4.8	Form of Warrant to Purchase Series H Convertible Redeemable Preferred Stock EX-4.8 Exhibit 4.8 PREFERRED STOCK PURCHASE WARRANT BIOLASE, INC. Preferred Warrant Shares: Initial Exercise Date: , 2023 Issuance Date: , 2023 THIS PREFERRED STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value of $0.001 received by the Company, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth
May 18, 2023	EX-4.7	Form of Warrant Agency Agreement Exhibit 4.7 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT (this “Warrant Agency Agreement”) dated as of [], 2023 (the “Issuance Date”) between BIOLASE, Inc., a company incorporated under the laws of the State of Delaware (the “Company”), and Computershare Inc., a Delaware corporation (“Computershare”), and its affiliate Computershare Trust Company, N.A., a federally chartered trust company (to
May 11, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36385 BIOLASE, INC. (Exa
May 11, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 BIOLASE, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36385 87-0442441 (State or Other Jurisdiction of Incorporation) (Commission File Number)
May 11, 2023	EX-99.1	BIOLASE MAINTAINS MOMENTUM AND REPORTS NINTH CONSECUTIVE QUARTER OF YEAR-OVER-YEAR GROWTH; REITERATES FULL YEAR GUIDANCE OF AT LEAST 25% REVENUE GROWTH AND PROFITABILITY FOR FULL YEAR 2023 Educational and Training Programs Introducing Broader Communi Exhibit 99.1 BIOLASE MAINTAINS MOMENTUM AND REPORTS NINTH CONSECUTIVE QUARTER OF YEAR-OVER-YEAR GROWTH; REITERATES FULL YEAR GUIDANCE OF AT LEAST 25% REVENUE GROWTH AND PROFITABILITY FOR FULL YEAR 2023 Educational and Training Programs Introducing Broader Community of Dentists to Experience Industry-Leading Dental Lasers for the First Time LAKE FOREST, Calif., May 11, 2023 – BIOLASE, Inc. (NASDAQ:
May 4, 2023	EX-FILING FEES	Filing Fee Table EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) BIOLASE, INC.
May 4, 2023	S-1	Power of Attorney (contained on the signature page of the initial registration statement) S-1 1 d84293ds1.htm S-1 Table of Contents As filed with the Securities and Exchange Commission on May 4, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIOLASE, INC. (Exact name of registrant as specified in its charter) Delaware 3843 87-0442441 (State or other jurisdiction of incor
May 3, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2023 BIOLASE, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36385 87-0442441 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
March 29, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under § 240.
March 28, 2023	EX-4	Description of Registrant's Securities Registered Pursuant to Section 12 of the Exchange Act EXHIBIT 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 BIOLASE, Inc. (“BIOLASE,” “we,” “us” or “our”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended, namely our common stock, par value $0.001 per share. This summary does not purport to be complete and is subject to t
March 28, 2023	EX-21	Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries BL Acquisition II, Inc. (Delaware) BL Acquisition Corp. (Delaware) Model Dental Office, LLC (Delaware) Biolase Australia, Pty. Ltd. (AUSTRALIA) Biolase Europe, GmbH (GERMANY) Biolase Spain, S.L. (SPAIN) Biolase India Private Limited (INDIA)
March 28, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36385 BIOLASE, INC.
March 28, 2023	EX-99	BIOLASE DELIVERS 24% REVENUE GROWTH IN 2022 AS GO-TO-MARKET STRATEGIES GAIN MOMENTUM; GUIDES FOR AT LEAST 25% REVENUE GROWTH AND PROFITABILITY IN 2023 Exhibit 99.1 BIOLASE DELIVERS 24% REVENUE GROWTH IN 2022 AS GO-TO-MARKET STRATEGIES GAIN MOMENTUM; GUIDES FOR AT LEAST 25% REVENUE GROWTH AND PROFITABILITY IN 2023 LAKE FOREST, Calif., March 28, 2023 – BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced its financial results for the fourth quarter and full year ended December 31, 2022. 2022 Full-Year Financial Highlig
March 28, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2023 BIOLASE, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36385 87-0442441 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
January 20, 2023	SC 13G	US0909114052 / BIOLASE INC / LYTTON LAURENCE W Passive Investment SC 13G 1 biolase13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Biolase, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 090911405 (CUSIP Number) January 10, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d
January 18, 2023	EX-99.1	BIOLASE MAINTAINS POSITIVE MOMENTUM THROUGH YEAR END WITH SOLID FOURTH QUARTER REVENUE GROWTH; SIGNIFICANT MARKET OPPORTUNITY AND INDUSTRY-LEADING PRODUCT SUPPORT EXPECTATION FOR ROBUST REVENUE GROWTH IN 2023 Exhibit 99.1 BIOLASE MAINTAINS POSITIVE MOMENTUM THROUGH YEAR END WITH SOLID FOURTH QUARTER REVENUE GROWTH; SIGNIFICANT MARKET OPPORTUNITY AND INDUSTRY-LEADING PRODUCT SUPPORT EXPECTATION FOR ROBUST REVENUE GROWTH IN 2023 Foothill Ranch, Calif., January 18, 2023 – BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced today that based on currently available information, prelim
January 18, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2023 BIOLASE, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36385 87-0442441 (State or Other Jurisdiction of Incorporation) (Commission File Num
January 13, 2023	SC 13G	US0909114052 / BIOLASE INC / Lind Global Fund II LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* BIOLASE, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 090911405 (CUSIP Number) January 10, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua
January 13, 2023	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 exhibit99-1.htm JOINT FILING AGREEMENT BY AND AMONG THE REPORTING PERSONS Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Stock, par value $0.001 per share, of Biolase, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule
January 12, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2023 BIOLASE, INC. (E UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2023 BIOLASE, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36385 87-0442441 (State or Other Jurisdiction of Incorporation) (Commission File Num
January 11, 2023	424B1	16,453,569 Shares of Common Stock and 11,403,571 Pre-Funded Warrants to Purchase One Share of Common Stock 11,403,571 Shares of Common Stock Underlying Pre-Funded Warrants BIOLASE, Inc. 424B1 Table of Contents Filed Pursuant to Rule 424(b)(1) Registration Number 333-268528 PROSPECTUS 16,453,569 Shares of Common Stock and 11,403,571 Pre-Funded Warrants to Purchase One Share of Common Stock 11,403,571 Shares of Common Stock Underlying Pre-Funded Warrants BIOLASE, Inc.
January 6, 2023	CORRESP	January 6, 2023 January 6, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Jessica Ansart Re: BIOLASE, Inc. Registration Statement on Form S-1 File No. 333-268528 Withdrawal of Acceleration Request Resubmission of Acceleration Request Ladies and Gentlemen: Please refer to the acceleration request (the “Prior Accelerat
January 6, 2023	CORRESP	[Signature Page to Follow] CORRESP 1 filename1.htm January 6, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Biolase, Inc. Registration Statement on Form S-1, as amended File No. 333-268528 Withdrawal of Acceleration Request Resubmission of Acceleration Request Ladies and Gentlemen: Reference is made to our letter, filed as correspondence
January 5, 2023	EX-10.1	Tenth Amendment to Credit Agreement, dated as of December 30, 2022, by and between the Registrant and SWK LLC EX-10.1 2 d404471dex101.htm EX-10.1 Exhibit 10.1 TENTH AMENDMENT TO CREDIT AGREEMENT THIS TENTH AMENDMENT TO CREDIT AGREEMENT (this “Amendment”), dated as of December 30, 2022, is entered into by and among BIOLASE, INC., a Delaware corporation (“Borrower”), each of the undersigned financial institutions (individually each a “Lender” and collectively “Lenders”) and SWK FUNDING LLC, a Delaware limit
January 5, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2022 BIOLASE, INC. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2022 BIOLASE, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36385 87-0442441 (State or Other Jurisdiction of Incorporation) (Commission File Nu
January 4, 2023	CORRESP	January 4, 2023 CORRESP 1 filename1.htm January 4, 2023 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Jessica Ansart Re: BIOLASE, Inc. Registration Statement on Form S-1 File No. 333-268528 Acceleration Request Requested Date: January 5, 2023 Requested Time: 5:00 P.M., Eastern Time Ladies and Gentlemen: Pursuant to Rule
January 4, 2023	CORRESP	[Signature Page to Follow] CORRESP 1 filename1.htm January 4, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Biolase, Inc. Registration Statement on Form S-1, as amended File No. 333-268528 Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of
January 3, 2023	EX-4.2	Form of Warrant to Purchase Common Stock issued on January 11, 2023 EX-4.2 Exhibit 4.2 FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT BIOLASE, INC. Warrant Shares: [ ] Initial Exercise Date: [ ], 2023 Issue Date: [ ], 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (this “Warrant”) certifies that, for value received, [ ], or [his/her/its] assigns (the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinaf
January 3, 2023	S-1/A	As filed with the Securities and Exchange Commission on January 3, 2023 S-1/A Table of Contents As filed with the Securities and Exchange Commission on January 3, 2023 Registration No.
January 3, 2023	EX-1.1	Form of Underwriting Agreement EX-1.1 Exhibit 1.1 FORM OF UNDERWRITING AGREEMENT BIOLASE, INC. [•], 2023 Lake Street Capital Markets, LLC As Representative of the several Underwriters named in Schedule I hereto c/o Lake Street Capital Markets, LLC 920 Second Avenue South, Suite 700 Minneapolis, Minnesota 55402 Ladies and Gentlemen: Biolase, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several
January 3, 2023	EX-FILING FEES	Filing Fee Table EX-FILING FEES 6 d417902dexfilingfees.htm EX-FILING FEES Exhibit 107.1 Calculation of Filing Fee Tables Form S-1 (Form Type) BIOLASE, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Maximum Aggregate Offering Price(1)(2) Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.001
December 12, 2022	EX-4.3	Form of Pre-Funded Warrant EX-4.3 Exhibit 4.3 FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT BIOLASE, INC. Warrant Shares: [ ] Initial Exercise Date: [ ], 2022 Issue Date: [ ], 2022 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (this “Warrant”) certifies that, for value received, [ ], or [his/her/its] assigns (the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinaf
December 12, 2022	S-1/A	As filed with the Securities and Exchange Commission on December 12, 2022 S-1/A Table of Contents As filed with the Securities and Exchange Commission on December 12, 2022 Registration No.
December 12, 2022	EX-1.1	Form of Underwriting Agreement EX-1.1 Exhibit 1.1 FORM OF UNDERWRITING AGREEMENT BIOLASE, INC. [•], 2022 Lake Street Capital Markets, LLC As Representative of the several Underwriters named in Schedule I hereto c/o Lake Street Capital Markets, LLC 920 Second Avenue South, Suite 700 Minneapolis, Minnesota 55402 Ladies and Gentlemen: Biolase, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several
December 12, 2022	EX-4.2	Form of Warrant EX-4.2 Exhibit 4.2 FORM OF COMMON STOCK PURCHASE WARRANT BIOLASE, INC. Warrant Shares: [ ] Initial Exercise Date: [ ], 2022 Issue Date: [ ], 2022 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [ ], or [his/her/its] assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any ti
December 12, 2022	EX-FILING FEES	Filing Fee Table EX-FILING FEES Exhibit 107.1 Calculation of Filing Fee Tables Form S-1 (Form Type) BIOLASE, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Maximum Aggregate Offering Price(1)(2) Fee Rate Amount of Registration Fee Equity Units consisting of: 457(o) $11,500,000 0.00011020 1,267.30 Equity (i) Co
November 22, 2022	S-1	Power of Attorney (contained on signature page to previously filed registration statement) S-1 Table of Contents As filed with the Securities and Exchange Commission on November 22, 2022 Registration No.
November 22, 2022	EX-FILING FEES	Filing Fee Table EX-FILING FEES Exhibit 107.1 Calculation of Filing Fee Tables Form S-1 (Form Type) BIOLASE, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Maximum Aggregate Offering Price(1)(2) Fee Rate Amount of Registration Fee Equity Units consisting of: 457(o) $17,250,000 0.00011020 1,900.95 Equity (i) Co
November 10, 2022	EX-99.1	BIOLASE DELIVERS 26% REVENUE GROWTH YEAR OVER YEAR IN THIRD QUARTER AND RAISES 2022 FULL YEAR REVENUE GUIDANCE Exhibit 99.1 BIOLASE DELIVERS 26% REVENUE GROWTH YEAR OVER YEAR IN THIRD QUARTER AND RAISES 2022 FULL YEAR REVENUE GUIDANCE LAKE FOREST, Calif., November 10, 2022 ? BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced its financial results for the third quarter ended September 30, 2022. 2022 Third Quarter Highlights ? Total revenue was $12.0 million, up 26% year over y
November 10, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 BIOLASE, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36385 87-0442441 (State or Other Jurisdiction of Incorporation) (Commission File Nu
November 10, 2022	EX-2.1	Membership Interest Purchase Agreement, dated as of September 22, 2022, by and among BIOLASE, Inc., Med-Fiber LLC and Alexei Tchapyjnikov Exhibit 2.1 Membership Interest Purchase Agreement This Membership Interest Purchase Agreement (this ?Agreement?), dated as of September 22, 2022, is entered into by and among Biolase, Inc., a Delaware corporation (?Buyer?), Med-Fiber LLC, a Maryland limited liability company (the ?Company?), and Alexei Tchapyjnikov, an individual resident of *** and sole member of the Company (?Seller? together w
November 10, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36385 BIOLASE, INC.
September 28, 2022	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2022 BIOLASE, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36385 87-0442441 (State or Other Jurisdiction of Incorporation) (Commission File N
August 19, 2022	S-3/A	As filed with the Securities and Exchange Commission on August 19, 2022 Table of Contents As filed with the Securities and Exchange Commission on August 19, 2022 Registration No.
August 19, 2022	CORRESP	Biolase, Inc. 27042 Towne Centre Drive, Suite 270 Lake Forest, California 92610 CORRESP 1 filename1.htm Biolase, Inc. 27042 Towne Centre Drive, Suite 270 Lake Forest, California 92610 August 19, 2022 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Margaret Schwartz Re: BIOLASE, Inc. Registration Statement on Form S-3, as amended File No. 333-266852 Acceleration Request Requested Date:
August 19, 2022	424B3	BIOLASE, INC. 1,405,405 SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF OUTSTANDING WARRANTS Table of Contents Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-266673 PROSPECTUS BIOLASE, INC. 1,405,405 SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF OUTSTANDING WARRANTS This prospectus relates to the possible resale of up to 1,405,405 shares of our common stock, $0.001 par value per share (?Common Stock?) that may be issued upon the exercise of certain warrants at an exerc
August 19, 2022	EX-FILING FEES	Filing Fee Table EXHIBIT 107.1 Calculation of Filing Fee Tables FORM S-3 (Form Type) BIOLASE, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly R
August 17, 2022	S-3/A	As filed with the Securities and Exchange Commission on August 17, 2022 Table of Contents As filed with the Securities and Exchange Commission on August 17, 2022 Registration No.
August 17, 2022	CORRESP	August 17, 2022 August 17, 2022 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Jordan Nimitz Re: BIOLASE, Inc. Registration Statement on Form S-3 File No. 333-266673 Acceleration Request Requested Date: August 19, 2022 Requested Time: 4:00 P.M., Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 under the Securities
August 12, 2022	EX-4.3	Form of Indenture (relating to the debt securities registered hereby) Exhibit 4.3 BIOLASE, INC. AND , as Trustee FORM OF INDENTURE Dated as of Debt Securities Reconciliation and tie between Trust Indenture Act of 1939, as amended, and the Indenture Trust Indenture Act Section Indenture Section ?310(a)(1) 6.8 (a)(2) 6.8 (b) 6.9 ?312(a) 7.1 (b) 7.2 (c) 7.2 ?313(a) 7.3 (b)(2) 7.3 (c) 7.3 (d) 7.3 ?314(a) 7.4 (c)(1) 1.2 (c)(2) 1.2 (e) 1.2 (f) 1.2 ?316(a) (last sentence)
August 12, 2022	S-3	Power of Attorney (contained herein on signature page) Table of Contents As filed with the Securities and Exchange Commission on August 12, 2022 Registration No.
August 12, 2022	EX-FILING FEES	Filing Fee Table EXHIBIT 107.1 Calculation of Filing Fee Tables FORM S-3 (Form Type) BIOLASE, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly R
August 11, 2022	EX-10.1	Ninth Amendment to Credit Agreement, dated as of June 30, 2022, by and between the Registrant and SWK Funding LLC Exhibit 10.1 NINTH AMENDMENT TO CREDIT AGREEMENT THIS NINTH AMENDMENT TO CREDIT AGREEMENT (this ?Amendment?), dated as of June 30, 2022, is entered into by and among BIOLASE, INC., a Delaware corporation (?Borrower?), each of the undersigned financial institutions (individually each a ?Lender? and collectively ?Lenders?) and SWK FUNDING LLC, a Delaware limited liability company, in its capacity as
August 11, 2022	EX-99.1	BIOLASE DELIVERS 34% REVENUE GROWTH YEAR OVER YEAR IN SECOND QUARTER BIOLASE DELIVERS 34% REVENUE GROWTH YEAR OVER YEAR IN SECOND QUARTER Lake Forest, Calif.
August 11, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 BIOLASE, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36385 87-0442441 (State or Other Jurisdiction of Incorporation) (Commission File Numb
August 11, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36385 BIOLASE, INC. (Exac
August 8, 2022	S-3	As filed with the Securities and Exchange Commission on August 8, 2022 Table of Contents As filed with the Securities and Exchange Commission on August 8, 2022 Registration No.

BIOLQ / BIOLASE, Inc. - SEC फाइलिंग, वार्षिक रिपोर्ट, प्रॉक्सी स्टेटमेंट

मूलभूत आँकड़े

SEC Filings

SEC Filings (Chronological Order)